Lanadelumab in Bradykinin Angioedema

Safety and Efficacy of Ranibizumab in Diabetic Macular Edema

NCT01131585 ·Status: TERMINATED ·Phase: PHASE3

Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab

NCT01402544 ·Status: TERMINATED ·Phase: PHASE2/PHASE3

Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema

NCT01476449 ·Status: COMPLETED ·Phase: PHASE2

Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema

NCT02055911 ·Status: WITHDRAWN ·Phase: PHASE4

Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (BRDME)

NCT01635790 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment

NCT01257815 ·Status: COMPLETED ·Phase: PHASE4

Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion

NCT02169648 ·Status: UNKNOWN ·Phase: NA

Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration

NCT02843490 ·Status: COMPLETED ·Phase: PHASE4

Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema

NCT02366468 ·Status: COMPLETED ·Phase: PHASE4

Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema

NCT02329132 ·Status: COMPLETED

Geographic Atrophy and Intravitreal Ranibizumab Injections

NCT02372916 ·Status: UNKNOWN

Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus

NCT01171976 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement

NCT00284050 ·Status: COMPLETED ·Phase: PHASE2

Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration.

NCT01831947 ·Status: COMPLETED ·Phase: PHASE4

Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration

NCT02140151 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Combination of Ranibizumab and Targeted Laser Photocoagulation

NCT04444492 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)

NCT03499223 ·Status: COMPLETED ·Phase: PHASE2

Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks

NCT01015495 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab

NCT01845844 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab

NCT01292798 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD

NCT01948830 ·Status: COMPLETED ·Phase: PHASE3

The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates

NCT02448446 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.

NCT01840410 ·Status: COMPLETED ·Phase: PHASE3

Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)

NCT00510965 ·Status: COMPLETED ·Phase: PHASE2

Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy

NCT01472510 ·Status: COMPLETED ·Phase: PHASE2